The deficiency of tumor suppressor prep1 accelerates the onset of meis1- hoxa9 leukemogenesis

PLoS One. 2014 May 8;9(5):e96711. doi: 10.1371/journal.pone.0096711. eCollection 2014.

Abstract

Prep1 and Meis1 ortholog TALE transcription factors have opposing roles in tumorigenesis: Meis1 serves as an oncogene, Prep1 as a tumor suppressor. We now report that, Meis1 overexpression in primary Prep1-deficient (Prep1i/i) embryonic hematopoietic cells increases self-renewal potential of cells in vitro but not in vivo, whereas leukemia is instead obtained when Meis1 is combined with another oncogene, HoxA9. Prep1i/i Meis1-HoxA9-generated leukemic cells are less differentiated and grow more aggressively after the second passage in the mouse. These data indicate that Prep1 represents a barrier to the transforming activity of Meis1 in vitro, but its absence is not sufficient to induce early leukemogenesis. On the other hand, the Prep1i/i background appears to favor the insurgence of mutations that cause a more aggressive Meis1-HoxA9-generated leukemia. Indeed, the Prep1i/i leukemic cells upregulate the Polycomb protein Bmi-1 and expectedly down-regulate the Ink4a/Arf locus products. Finally, an important feature contributed by the Prep1i/i background is the post-transcriptional increase in Meis1 protein level.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Carcinogenesis*
  • Cell Differentiation
  • Cell Line, Tumor
  • Cell Proliferation
  • Cell Transformation, Neoplastic
  • Fetus / pathology
  • Homeodomain Proteins / genetics
  • Homeodomain Proteins / metabolism*
  • Leukemia / pathology*
  • Liver / pathology
  • Mice
  • Mutation
  • Myeloid Ecotropic Viral Integration Site 1 Protein
  • Neoplasm Proteins / genetics
  • Neoplasm Proteins / metabolism*
  • Phenotype
  • Tumor Suppressor Proteins / deficiency*

Substances

  • Homeodomain Proteins
  • Meis1 protein, mouse
  • Myeloid Ecotropic Viral Integration Site 1 Protein
  • Neoplasm Proteins
  • Pknox1 protein, mouse
  • Tumor Suppressor Proteins

Grants and funding

Leila Dardaei was supported by FUV (Fondazione Umberto Veronesi) fellowship. This work was supported by grants from AIRC (Italian Association for Cancer Research), Cariplo, and the Italian Ministry of Health to FB. The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.